The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects

Xenobiotica

Volumn 46, Issue 1, 2016, Pages 34-39

  Shang, Dewei ^a   Deng, Shuhua ^a   Yao, Zhenhong ^b   Wang, Zhanzhang ^a   Ni, Xiaojia ^a   Zhang, Ming ^a   Hu, Jinqing ^a   Lu, Haoyang ^a   Zhu, Xiuqing ^b   Huang, Wencan ^a   Qiu, Chang ^a   Wen, Yuguan ^a  

^a Institution of National Drug Clinical Trials of Guangzhou Brain Hospital   (China)

^b HaiNan HuaLon Pharmaceutical Co Ltd   (China)

Author keywords

Bioequivalent; food effect; pharmacokinetics; pitavastatin

Indexed keywords

GENERIC DRUG; PITAVASTATIN; PITAVASTATIN D5 SODIUM; UNCLASSIFIED DRUG; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; CHINESE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG TOLERABILITY; FEEDING; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; LIPID DIET; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; NORMAL VALUE; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; FOOD; HEALTH; MEDICINAL CHEMISTRY; REPRODUCIBILITY; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY, PHARMACEUTICAL; FOOD; HEALTH; HUMANS; MALE; QUINOLINES; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84955186712     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1046153     Document Type: Article

References (31)

1. Ando H, Tsuruoka S, Yanagihara H, et al. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 60:494-7.
2. Aoki T, Nishimura H, Nakagawa S, et al. (1997). Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase. Arzneimittelforschung 47:904-9.
3. Catapano LA. (2012). Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 10:257-67.
4. Charman WN, Porter CJ, Mithani S, et al. (1997). Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86:269-82.
5. Chen Y, Zhang W, Huang WH, et al. (2013). Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol 69:1933-8.
6. ChP, (Edition 2010). Guideline on the investigation of bioavailability and bioequivalence study of drug products. Appendix XIX B. 195.
7. Chung JY, Cho JY, Yu KS, et al. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers & ast. Clin Pharmacol Ther 78:342-50.
8. Fujino H, Yamada I, Kojima J, et al. (1999). Studies on the metabolic fate of NK-104, a new inhibitor of HMGCoA reductase: in vitro metabolism and plasma protein binding in animals and human. Drug Metab Pharmacokinet 14:415-24.
9. Fujino H, Yamada I, Shimada S, et al. (2003). Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDPglucuronosyl transferase enzymes involved in lactonization. Xenobiotica 33:27-41.
10. Hirano M, Maeda K, Shitara Y, et al. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-46.
11. Hu M, Mak VW, Yin OQ, et al. (2012). Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet 28:104-8.
12. Huang YH, Li ZQ, Pan GX, et al. (2014). Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. Clin Ther 36:1205-16.
13. Ieiri I, Higuchi S, Sugiyama Y. (2009). Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-29.
14. Inagaki Y, Hunt T, Arana B, et al. (2011). Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 51:1302-9.
15. Lv H, Sun JG, Wang GJ, et al. (2007). Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers. Clin Chim Acta 386: 25-30.
16. Maejima T, Yamazaki H, Aoki T, et al. (2004). Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 324:835-9.
17. Malvestutto CD, Ma Q, Morse GD, et al. (2014). Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ ritonavir. J Acquir Immune Defic Syndr 67:390-6.
18. Mukhtar RYA, Reid J, Reckless JPD. (2005). "Pitavastatin". Int J Clin Pract 59:239-52.
19. Ose L, Budinski D, Hounslow N, et al. (2009). Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 25:2755-64.
20. Pasanen MK, Neuvonen PJ, Niemi M. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19-33.
21. Qi X, Ding L, Wen A, et al. (2013). Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal 72: 8-15.
22. Requena-Méndez A, Davies G, Waterhouse D, et al. (2014). Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob Agents Chemother 58: 7164-70.
23. Saiki A, Murano T, Watanabe F, et al. (2005). Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 12:163-8.
24. Saito Y, Yamada N, Teramoto T, et al. (2002). A randomized, doubleblind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162:373-9.
25. Sasaki J, Ikeda Y, Kuribayashi T, et al. (2008). A 52-week, randomized, open-label, parallel group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of lowdensity lipoprotein cholesterol and glucose intolerance. Clin Ther 30:1089-101.
26. Schachter M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin Pharmacol 19:117-25.
27. Tirona RG. (2005). Ethnic differences in statin disposition. Clin Pharmacol Ther 78:330-41.
28. Wen J, Xiong Y. (2010). OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 35:99-104.
29. World Medical Association. (2013). Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191-4.
30. Xu LY, He YJ, Zhang W. (2007). Organic anion transporting polypeptide- 1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28: 1693-7.
31. Yee LL, Wright EA. (2011). Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. Clin Ther 33:1023-42.